N-Morpholinyllysergamide (developmental code name LSM-775), also known as lysergic acid morpholide, is a derivative of ergine (lysergamide).[2] It is less potent than lysergic acid diethylamide (LSD) but is reported to have some LSD-like effects at doses ranging from 75 to 700 micrograms and a shorter duration.[3] LSM-775 may only produce weak or threshold psychedelic effects in humans.[4]
 | |
| Clinical data | |
|---|---|
| Other names | LSM-775, N-Morpholinyllysergamide, Lysergic acid morpholide |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | hepatic |
| Excretion | renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H23N3O2 |
| Molar mass | 337.423 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
The drug is a potent full agonist of the serotonin 5-HT1A receptor and a potent partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[4] It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[4] However, LSM-775 can robustly increase head twitches if it is coadministered with the serotonin 5-HT1A receptor antagonist WAY-100635.[4] These findings indicate that serotonin 5-HT1A receptor activation suppresses the psychedelic-like effects of LSM-775.[4]
There are claimed to be fewer signs of cardiovascular stimulation and peripheral toxicity with LSM-775 compared to LSD.[3][dubious – discuss]
See also
edit- 1cP-LSD
- 1B-LSD
- 1P-ETH-LAD
- 1P-LSD
- 1V-LSD
- ALD-52
- AL-LAD
- ETH-LAD
- Lysergic acid 2,4-dimethylazetidide (LSZ)
- Lysergic acid diethylamide (LSD)
- O-Acetylpsilocin (4-AcO-DMT)
- PRO-LAD
References
edit- ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants" [Order of May 20, 2021 amending the order of February 22, 1990 setting the list of substances classified as narcotics]. www.legifrance.gouv.fr (in French). 20 May 2021.
- ^ Gogerty JH, Dille JM (July 1957). "Pharmacology of d-lysergic acid morpholide (LSM)". The Journal of Pharmacology and Experimental Therapeutics. 120 (3): 340–348. PMID 13476356.
- ^ a b Shulgin A, Shulgin A. "TiHKAL #26, LSD-25". Erowid.
- ^ a b c d e Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL (February 2018). "Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)". Drug Test Anal. 10 (2): 310–322. doi:10.1002/dta.2222. PMC 6230476. PMID 28585392.